Publications
5674 Results
- Journal / Conference
- Blood 119(13):3003-3015
- Year
- 2012
- Research Committee(s)
- Myeloma
- PMID
- PMID22271445
- PMC
- PMC3321864
IMWG consensus on maintenance therapy in multiple myeloma
- Journal / Conference
- Clinical Cancer Research 18(1):256-2662
- Year
- 2012
- Research Committee(s)
- Multiple sites and Outcomes and Comparative Effectiveness
Achieving sufficient accrual to address the primary endpoint in phase III clinical trials from U.S. cooperative group trials
- Journal / Conference
- Blood 120(19):3898-3905;
- Year
- 2012
- Research Committee(s)
- Leukemia
- PMID
- PMID22915637
- PMC
- PMC3496952
- Study Number(s)
- S0325
A randomized trial of dasatinib 100 mg vs imatinib 400 mg in newly diagnosed chronic phase chronic myeloid leukemia
- Journal / Conference
- Clinical Cancer Research 18(3):890-900
- Year
- 2012
- Research Committee(s)
- Gastrointestinal
- Study Number(s)
- C89803
Predictive and prognostic roles of BRAF mutation in stage III colon cancer: results from the intergroup trial CALBG 89803 [PMID22147942; PMC3271172]; https://www.ncbi.nlm.nih.gov/pubmed/22147942
- Journal / Conference
- Lancet 379(9814):432-444
- Year
- 2012
- Research Committee(s)
- Breast
- PMID
- PMID22152853
- PMC
- PMC3273723
- Study Number(s)
- SWOG-8814
Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100,000 women in 123 randomised trials
- Journal / Conference
- Journal of the National Cancer Institute 104(20):1534-1541;
- Year
- 2012
- Research Committee(s)
- Multiple sites
- PMID
- PMID22927506
- PMC
- PMC3708548
When progressive disease does not mean treatment failure: reconsidering the criteria for progression
- Journal / Conference
- International Journal of Radiation Oncology, Biology & Physics 84(3):suppl., p S156; ASTRO 2012 Annual Meeting, oral;
- Year
- 2012
- Research Committee(s)
- Lung
- Study Number(s)
- S0533
Initial cooperative group experience of bevacizumab (BEV) plus concomitant chemoradiotherapy (CRT) in patients with inoperable locally advanced stage III non-small cell lung cancer (LA-NSCLC): preliminary results of S0533
- Journal / Conference
- Blood 120(6):1210-1217
- Year
- 2012
- Research Committee(s)
- Lymphoma
- PMID
- PMID22734071
- PMC
- PMC3418716
- Study Number(s)
- S0515
A phase II trial of R-CHOP plus bevacizumab for patients with newly diagnosed diffuse large b-cell non-hodgkin lymphoma: SWOG 0515
- Journal / Conference
- Contemporary Clinical Trials 33(6):1117-1123;
- Year
- 2012
- Research Committee(s)
- Breast
- PMID
- PMID2298189
- PMC
- PMC3486702
- Study Number(s)
- S1007
The value of comparative effectiveness research: projected return on investment of the RxPONDER trial (SWOG S1007)
- Journal / Conference
- New England Journal of Medicine 367(10):895-903
- Year
- 2012
- Research Committee(s)
- Genitourinary
- PMID
- PMID22931259
- PMC
- PMC3521033
- Study Number(s)
- JPR7